Synthes partners with Kuros Biosurgery to develop biomaterials for spinal applications |

Synthes partners with Kuros Biosurgery to develop biomaterials for spinal applications

Kuros and Synthes, Inc. Announce License and Development Agreement (press release)

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactivebiomaterial combination  products for trauma, wound and spinal indications has signed a license and development agreement with Synthes, Inc. a leading global medical device company.

Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields. Commenting on today’s announcement, Mr. Didier Cowling, CEO of Kuros, said: “We are delighted to have signed this deal related to our synthetic matrix technologies with Synthes.

Partnering our products with leading marketing partners is a key element of Kuros’ strategy and we are looking forward to a productive working relationship with Synthes”.  Michel Orsinger, President and CEO of Synthes, commented on the partnership: “The Kuros partnership is an important addition to Synthes goal of being a total solutions provider for our customers. The partnership will strengthen both Kuros and Synthes commitment to develop patient focused clinical solutions.”

Kuros has a broad platform of technologies related to biomaterials and the combination of biomaterials with bioactive molecules. This platform has the potential to be used across many fields and includes synthetic matrices either alone or in combination with bioactives.

About Kuros (www.kuros.ch)

Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications. Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes. These materials can be used alone or in combination with biologically active molecules.

The synthetic technology is tailorable and allows generation of products that are delivered as liquids or gels but polymerise, in or on living tissues, to form materials with different physical properties. Kuros’ has a diverse pipeline of product candidates with its most advanced product candidates being in trauma and wound care.

Since its creation, Kuros has raised over $200 million. The company is located in Zurich, Switzerland

Leave a Reply

Your email address will not be published. Required fields are marked *